Ignt off to a slow start today. Stock had news today. I looked at the charts on this one too. I think this one might bounce back. Look into this one and check the company out
Ignt looking like a strong buy today while the stock is dipping. Good time to load up on this one. Imo this one will run at the end of the day and next week.
IGNT closed @ .002 looking to break next resistance of .0021 (50 day MA). Over the last two weeks of trading, IGNT HOD has reached anywhere between .023-.032; hopefully we continue to see this trend to see some price appriciation.
Press Release Source: Ingen Technologies, Inc. On Wednesday January 20, 2010, 8:15 am EST
YUCAIPA, Calif., Jan. 20, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that the current quarter sales represented an increase of 17.7% from sales in the quarter ended November 30, 2008. Sales were sparked by the introduction of Oxyview Nasal Cannula unit that includes a cannula with Ingen’s Oxyview unit. Additional capital also enabled the company to increase the advertising and marketing of the Oxyview products. Ingen anticipates that the sales of Oxyview will increase from the current quarter’s sales as the Company expands its sales channels.
The total cost of sales for the quarter ended November 30, 2009 has a gross margin of 90.8%. The reported cost of sales for the quarter ended November 30, 2008 had a gross margin of 89.4%. The Company anticipates that its gross margin will continue to stay in the range of the current quarter.
The largest components of Ingen’s SG&A are advertising, legal and professional services, travel associated with both sales and business development, outside services and salaries. The advertising expense increased from zero in the quarter ended November 30, 2008 to $41,090 in the quarter ended November 30, 2009. The Company expects to continue advertising at current levels as it continues to promote Oxyview.
The Company has reduced its debt to the note holders by $2.3M, and expects to reduce the entire balance by March-2010. The company anticipates a share buy-back program for all of its shareholders once the note is paid in full.
The company projects that the Oxyview Nasal Cannula will bring $10M in revenues, and the new Oxyview Pulse Oximeter an additional $1M in revenues in 2010.
Press Release Source: Ingen Technologies, Inc. On Wednesday January 27, 2010, 8:15 am
YUCAIPA, Calif., Jan. 27, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that it has approved an insertion order with COPD Foundation's new magazine that targets 20,000-30,000 lung specialists that includes physicians, respiratory therapists, nurse practitioners, and other lung specialists.
The company already has a 12 month contract with the COPD Foundation's COPD Digest magazine that is distributed once each quarter to over 200,000 subscribers. The new magazine will be released next month and includes articles and submissions by a variety of academics and clinicians, and will be focused on articles of interest to those treating patients with pulmonary diseases. These lung specialists represent 15,000,000 patients with COPD and various lung disorders in the USA.
"We look forward to working with Mitch Ruttner of the COPD Foundation and supporting the efficacy of their program. Mr. Ruttner has also been very proactive with our Oxyview product line, as we continue to direct a strong focus in the commercial hospital markets to sell our products. We continue to see an increase with hospital orders for bulk purchases, and this is an indicator that our Oxyview products are being recognized by hospitals. We are very appreciative for all of the support Ingen continues to receive from credible sources and shareholders," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
Ingen is an established medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company has domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the Oxyview Nasal Cannula was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced the Oxyview Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Ignt had news today.Stock is trading well today. Myself and other smart money have taken a position in this stock today. We should see more price aprecation today and this week. The new magazine insert should bring more focus towards the company and the great products they produce. This company has a bright future and we can all profit from it. Remember this is my opinion and to do your own dd. Hope all your stocks are in the green
Press Release Source: Ingen Technologies, Inc. On Tuesday February 9, 2010, 8:15 am
YUCAIPA, Calif., Feb. 9, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that the company was granted approval of the Stage-I audit conducted by BSI America, Inc. on February 5, 2010.
On February 5, 2010 the company was audited by Mr. Brian Nguyen, one of the certified auditors with BSI America, Inc. According to Mr. Nguyen, Ingen's management system documentation meets the requirements of the ISO 13485:2003, the MDD 93/42/EEC Annex V (M5), and the CMDR. The internal audits and management review processes are being planned and performed. Based on the objective evidences noted from the areas assessed during this Stage-I audit, it is recommended that Ingen proceed to the final Stage-II audit. There were no outstanding non-conformities to review from previous assessments. No new non-conformities were identified during the assessment.
Ingen Technologies is strongly committed to the success of this company and continues driving forward in a direction that is within the best interest of its shareholders. The company has pending back-orders for export sales to China, Japan, Canada, Europe and Australia. Ingen has seen an increase in the value with its intellectual property, research & development, new medical product lines, inventory and other assets, while revenues show a steady incline. ISO Certification is expected to result in a large revenue jump of the company's respiratory product lines.
TYUCAIPA, Calif., Feb. 18, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced today that the CEO and Chairman of the Board, Scott R. Sand, has issued the following statement.
"Ingen Technologies is focused on increasing the sales and marketing of its respiratory product line. We have passed Stage-I of our ISO Certification audit, and expect to pass Stage-II on March 1, 2010. This ISO certification opens doors to Europe, Asia, Canada and Australia where our products are needed more, and where we currently have back-orders pending ISO certification. COPD is the 4th cause of death in the USA and Canada, and the first leading cause of death in Europe and Asia, and this is why there is a greater demand of our Smart Nasal Cannula with Oxyview, and our new I-Pulse Oximeter. We expect to meet our 2010 projections of $11M in sales. Israel is our newest distribution partner, as we discuss details with Elul Medical Assistance Services Ltd."
"There is no reverse split authorized or being discussed. We have strong investment commitments to assist the company with a stock buy-back program. In order to comply with the forbearance agreement with the N.I.R. Group, we will seek majority vote from our shareholders to increase the authorized so that we can pay off the balance of the note owed to the various funds managed by the N.I.R. Group and move forward with the share buy-back program. We have signed an aggressive PR contract with Accelerize New Media and the OTCRoadshow.com to support and strengthen shareholder value over the next few months. Currently the company has paid off the majority of its debts, and has reduced the NIR debt down from $4.5M to $2.2M in the past 5 months. When this debt is cured, we will begin the share buy-back program. We continue to have a sufficient cash reserve, and our product sales continue to show a steady incline, despite the fact that we have not gained ISO certification as of now."
"Our pending GSA contracts are expected to be approved very soon, and these contracts will also greatly improve our distribution and product sales. KGMA Business Solutions has recently begun introducing our products and negotiating national distribution contracts for VA Hospitals and the Department of Defense. We will make an announcement in 2 weeks regarding their progress."
"We are not out of the woods just yet, however. We have a strong commitment to our shareholders and to the success of this company, and there is no doubt that our medical products are now on the way to creating the revenues and recognition that they deserve in the marketplace. The company will be introducing another new proprietary and innovative product in April-2010 for the drug industry. The heart of our success lies within the risks we have taken and our belief in these new medical products and success for this company. With all of this said, we continue to seek the support from our shareholders, and look for success in the near future to come," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
IGNT reported a 17.7% increase in sales for its last two quarters, with an expected larger increase over the next two quarters as its Oxyview product line continues to gain acceptance in the marketplace as the next generation of oxygen therapy devices.
Last edited by Jonathan Devine; 03-03-2010 at 10:13 AM.
YUCAIPA, Calif., March 2, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News), a leading manufacturer of respiratory medical devices, recently announced that it has increased its marketing and advertising budget now that ISO Certification is near completion, and the Government Services Administration application is near approval.
Ingen will debut the new I-Pulse Oximeter and the new Smart Nasal Cannula with Oxyview technology this coming spring at MedTrade in Las Vegas, the American Thoracic Society in New Orleans, and the Alpha-1 Association's National Education Conference in Orlando.
On May 12, 2010, Ingen will be an exhibitor at the MedTrade Spring convention in Las Vegas, Nevada. The convention connects the HME industry, and allows respiratory leaders to stay ahead of HME industry changes and find the latest tools to help their clients. This is the largest home medical equipment convention in the western U.S. and brings more exhibitors, more ideas, and more products than ever before together under one roof. This is Ingen's opportunity to develop strategic OEM partners and new distributors for the Oxyview product line.
On May 14, 2010, Ingen's consulting partner, MedCo Forum, will introduce the Oxyview product line at the American Thoracic Society in New Orleans, Louisiana. The American Thoracic Society (ATS) is committed to disseminating the latest advances, nationally and internationally, in the fields of lung disease, sleep disorders and critical care medicine. The annual International Conference has become the premier, international forum for physicians and scientists who work in pulmonary, critical care, and sleep medicine. The company will reach 13,000 pulmonologists through the advertising in MedCo Forum's ATS issue that is scheduled to be released on May 1, 2010. MedCo Forum will also host the Oxyview advertising on their website.
On June 11, 2010, Ingen will be an exhibitor at the Alpha-1 Association's National Education Conference in Orlando, Florida. The Alpha-1 Association is a member-based not-for-profit organization dedicated to identifying those affected by Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improve the quality of their lives through support, education, advocacy and to encourage participation in research. Alpha-1-Antitrypsin Deficiency (Alpha-1) is a genetic disorder that can cause liver and lung disease in children and adults.
"We look forward to attending these major conventions this spring as we continue to make progress with the introduction of the new I-Pulse Oximeter and the Smart Nasal Cannula with Oxyview technology. We thank all of our shareholders for their continued support and look forward to a very successful future for everyone," stated Scott R. Sand, Chief Executive Officer and Chairman of the Board.
LinkBack URL
About LinkBacks
IGNT Ingen Technologies Inc.
Reply With Quote
Posting Permissions
FOLLOW US
in Social media